Last reviewed · How we verify
Engerix-B and Twinrix
These vaccines stimulate the immune system to produce antibodies against hepatitis A and/or B viruses, providing protective immunity.
These vaccines stimulate the immune system to produce antibodies against hepatitis A and/or B viruses, providing protective immunity. Used for Prevention of hepatitis B infection, Prevention of hepatitis A and B infection (Twinrix).
At a glance
| Generic name | Engerix-B and Twinrix |
|---|---|
| Sponsor | St. Joseph's Health Care London |
| Drug class | Vaccine |
| Target | Hepatitis B surface antigen (HBsAg); Hepatitis A virus antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Engerix-B is a recombinant hepatitis B vaccine that contains hepatitis B surface antigen (HBsAg) produced in yeast cells, which triggers B-cell and T-cell responses to generate protective antibodies. Twinrix is a combination vaccine containing both hepatitis A inactivated virus and hepatitis B recombinant surface antigen, providing dual protection against both viruses through similar immune mechanisms.
Approved indications
- Prevention of hepatitis B infection
- Prevention of hepatitis A and B infection (Twinrix)
Common side effects
- Injection site soreness, redness, or swelling
- Fatigue
- Headache
- Myalgia
- Low-grade fever
Key clinical trials
- A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
- Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc (PHASE4)
- Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult (PHASE4)
- Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult (PHASE4)
- Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule (PHASE3)
- Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination (PHASE4)
- Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth (PHASE4)
- Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Engerix-B and Twinrix CI brief — competitive landscape report
- Engerix-B and Twinrix updates RSS · CI watch RSS
- St. Joseph's Health Care London portfolio CI